Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. - Wikidata - wikimedia - TriplyDB

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

http://www.wikidata.org/entity/Q42924716

about

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia Childhood acute lymphoblastic leukemia: Integrating genomics into therapy Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Childhood B-acute lymphoblastic leukemia: a genetic update.Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors Characterization of leukemias with ETV6-ABL1 fusion Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.Genomics in acute lymphoblastic leukaemia: insights and treatment implications.Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.Novel therapy for childhood acute lymphoblastic leukemia.Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.Philadelphia chromosome-like acute lymphoblastic leukemia.Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.Molecular processes involved in B cell acute lymphoblastic leukaemia.How is the Ph-like signature being incorporated into ALL therapy?A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).TP53 in adult acute lymphoblastic leukemia.The added values of multiplex reverse transcriptase-PCR followed by mutation screening in the initial evaluation of acute leukemia.Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.

P2860

ae50270c339ab5570b317ae3d3531a50437d4608

P248

Q26749177-19E06813-8DEA-4A24-9EFE-3D390DAD59EF Q28080463-7444FA1F-BE57-4307-8A61-85B0A942FB08 Q28087637-B0208B0E-227B-46A3-AAF4-19E5E0698BB0 Q30243925-EBC942AF-CFEC-46AA-9BF7-34DF6119AABF Q33718814-54EAF614-C24C-4705-A383-4CDBE7C5C5D2 Q33770150-CDEC8983-EE14-4E6E-8368-CDFDE854E222 Q33777616-42368DD0-8268-4C42-B0BE-16C755BDC033 Q34172033-434496DF-3A9D-4330-9386-9F206A48743F Q34314927-38758E16-EC41-4955-A051-756565B24EC2 Q36571783-7B148033-F678-4BBB-B811-00148953D2A3 Q37027102-8496EDAB-784A-4036-AD76-C65995604A16 Q37216300-75A3F78E-3180-473E-AEB0-99165DDFCFA7 Q37331221-4E6303CF-483C-44DE-9D71-07124733239A Q38264774-98113F29-3A96-480F-AD0F-573D981DFCF1 Q38289046-BFB1740F-B10A-424F-9ED0-692FA4192CC6 Q38289596-E69AAC59-E99E-4019-8C4E-37512A5A3149 Q38381463-B70DC0FE-088E-45BD-B91F-EA1DF1C52509 Q38492313-9F420A48-5AC3-4930-A8F8-974D5428C532 Q38734309-B1F550E6-D8F6-421C-AB8A-5326726D23E2 Q39123286-1695CE88-5824-4557-A3BB-7A65958BFF3C Q39128765-188E19C1-AFA3-4F40-ABDC-A83A0E90AF93 Q39139762-0B17F82E-6784-4B2F-A0A9-6EC3324F95DD Q39368957-102E0706-4B33-4BD3-927D-FA1F61061AE8 Q42315787-323E7E5B-7892-4393-8FDA-3DA96D4ABD8D Q42371687-A9341B9E-6A16-4BD4-B805-C1CE7D95736D Q42384528-CF2C0F74-81BB-48BD-9C73-1E0B6FFAD20F Q42720673-DCC4004A-B13C-4606-B7FF-49560CAB4B87 Q42943355-F1556C35-3B6C-4486-A242-CB8DC6329297 Q43431904-41C33CB0-EB19-4FD7-804B-79D59997CCE2 Q44018556-7948FEA1-72D8-4C39-829E-ADCA1757B17E Q47107172-06B16E19-EFF6-4FAF-996C-A75AB98AEEAE Q48218289-B9895B0E-BBFA-4DC4-AB43-653136219B0E Q50098629-E3E3CDF6-0C1B-40DB-85DA-3B31B6B9B7DF Q50327439-26CC970A-FFF0-49B7-922F-D451473B40B9 Q50547293-CBC837B9-F901-4450-87CB-D984B4975659 Q50906605-7FBC61C1-303D-41D5-BC9C-9983DF40CEC7 Q51694552-27FB95CB-E185-4CBF-AC1F-A08A8799C841 Q52575378-3E20C474-6D37-4947-87D9-179A6F825CE8 Q53261767-9211F1E8-D15C-445F-B124-82420FEA27E9 Q54309446-F43E1391-59F3-4625-91DA-DBAA546B3572

P2860

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

http://www.wikidata.org/entity/Q42924716

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@en

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@nl

type

label

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@en

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@nl

prefLabel

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@en

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@nl

P1433

Q42924716-381669A2-2708-4A10-98BB-D8493F04B638

P1476

Q42924716-585B5EE4-B5B7-4935-A524-130B93F05714

P2093

Q42924716-13FA4471-936B-4277-A8C7-F46FF5A7EAA2

Q42924716-57ABE136-E97B-4864-A7A7-26DC0D1717CA

Q42924716-84754EC9-2EB4-4FD9-A7A0-0B6E046C6F01

Q42924716-E3F25EA8-7182-4B84-95E1-BB75AD22EF2B

P2860

Q42924716-09C4D7FB-5E5A-4385-9CB3-DA4161DB8486

Q42924716-23E88D31-40CA-462F-A2A4-8834868F240F

Q42924716-2A3C0301-5E62-4AF4-B286-3A71D926CC3C

Q42924716-441BF543-AA7F-4561-AC30-4DC7311F975F

Q42924716-6100723C-CDA5-4769-B0C3-4E3C2D46EBC7

Q42924716-80B0AE3D-2D43-4785-A678-C5680778FD6C

Q42924716-93B11321-151C-40B9-A23E-F8BA3B15B387

Q42924716-B8C0AFE6-0229-48BD-BB7B-AF28388D33D1

Q42924716-DE655C6D-E2AF-42BE-8560-6CFB16B05450

Q42924716-EE326CD0-2914-490F-ABD3-EF27DF2AD2AE

P304

Q42924716-1273CF49-C05D-420B-B60A-D2E8655E6A00

P31

Q42924716-4E140051-9A1C-47D8-B460-73ED80C0B412

P356

Q42924716-F2921071-5707-45DE-9D30-FE3101243E8F

P433

Q42924716-E13BECCD-4352-471F-9A1B-BC9054A2C46B

P478

Q42924716-89558074-11DD-4848-9425-B242D5DC68B6

P50

Q42924716-13901A98-58D5-4902-A6E1-E6E2A07A9916

Q42924716-678D6A5D-4D53-4569-9B76-9433F5814307

P577

Q42924716-B2759868-B24E-4CD8-B126-E60659D772AC

P698

Q42924716-20D6A5DA-13EE-48BA-ADE7-E8E613B0A16E

P921

Q42924716-13764B8E-E71B-4684-9A4E-C451D127E472

P932

Q42924716-7B91F5B1-CBFC-41FA-9454-104701EB5B86

P356

HAEMATOL.2013.095372

P1433

P1476

Successful tyrosine kinase inh ...... kemia with EBF1-PDGFRB fusion.

@en

P2093

Emmanuelle Clappier

http://www.w3.org/2001/XMLSchema#string

Jean Soulier

http://www.w3.org/2001/XMLSchema#string

Kheïra Beldjord

http://www.w3.org/2001/XMLSchema#string

Nicolas Boissel

http://www.w3.org/2001/XMLSchema#string

P2860

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.

The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Failure of B-cell differentiation in mice lacking the transcription factor EBF.

Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

P304

e146-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2013.095372

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Etienne Lengline

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24186319

http://www.w3.org/2001/XMLSchema#string

P921

P932

3815191

http://www.w3.org/2001/XMLSchema#string